TargetMol

GI254023X

Product Code:
 
TAR-T7522
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7522-1mg1mg£126.00
Quantity:
TAR-T7522-2mg2mg£161.00
Quantity:
TAR-T7522-5mg5mg£191.00
Quantity:
TAR-T7522-10mg10mg£242.00
Quantity:
TAR-T7522-25mg25mg£421.00
Quantity:
TAR-T7522-50mg50mg£605.00
Quantity:
TAR-T7522-100mg100mg£816.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Austria.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
GI254023X is a potent MMP9 and ADAM10 inhibitor (IC50s: 2.5 and 5.3 nM) with 100-fold selectivity for the α-secretase ADAM10 over ADAM17 (TACE). GI254023X can remarkably inhibit the proliferation and induce the apoptosis of H929 cells. Its mechanism may be associated with inbihition of Notch1 activation.
CAS:
260264-93-5
Formula:
C21H33N3O4
Molecular Weight:
391.5
Pathway:
Proteases/Proteasome; Immunology/Inflammation
Purity:
0.9856
SMILES:
O=C(N[C@H](C(NC)=O)C(C)(C)C)[C@@H]([C@@H](N(C=O)O)C)CCCC1=CC=CC=C1
Target:
MMP; Immunology/Inflammation related

Documents

References

Shackleton B, et al. Inhibition of ADAM10 promotes the clearance of A? across the BBB by reducing LRP1 ectodomain shedding. Fluids Barriers CNS. 2016 Aug 8;13(1):14. Verena V. Metz, et al. Induction of RAGE Shedding by Activation of G Protein-Coupled Receptors. PLoS One. 2012. N Milosch, et al. Holo-APP and G-protein-mediated signaling are required for sAPPa-induced activation of the Akt. Cell Death Dis. 2014 Aug 28;5:e1391. M J M Gooden, et al. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. British Journal of Cancer (2014) 110, 1535?1544.